TransCode Therapeutics Inc RNAZ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio
TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026
TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026
TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up
TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology
Join Today's Live Investor Webinar with TransCode Therapeutics
TransCode Therapeutics Announces Leadership Transition
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer
Trading Information
- Previous Close Price
- $1.60
- Day Range
- $1.48–1.67
- 52-Week Range
- $0.00–12.60
- Bid/Ask
- $1.45 / $1.60
- Shares Outstanding
- 16.93M
- Market Cap
- $25.57M
- Volume/Avg
- 123 / 54,041
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
Metric | RNAZ |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RNAZ
Financial Strength
Metric | RNAZ |
|---|---|
Quick Ratio | 1.55 |
Current Ratio | 1.97 |
Interest Coverage | −6,550.78 |
Quick Ratio
RNAZ
Profitability
Metric | RNAZ |
|---|---|
Return on Assets (Normalized) | −36.73% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −40.38% |
Return on Assets
RNAZ
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|&hbsb!? | LOCK|TDSY | $138B | |||
| Moderna Inc MRNA | LOCK|@@^qS$M | LOCK|hx | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|@@@@y$# | LOCK|b@rH | $93B | |||
| argenx SE ADR ARGX | LOCK|<<#vmj | LOCK|XFr | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|bd&>w@< | LOCK|nP | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Vx@?t#% | LOCK|@h^x? | $30B | |||
| Incyte Corp INCY | LOCK|ln^py# | LOCK|$Zq | $24B | |||
| BioNTech SE ADR BNTX | LOCK|JMb$P$ | LOCK|j?b | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|L@b!&vB | LOCK|<LZZL | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%?ZXxt | LOCK|@X# | $15B |
United States